[Translation] A single-center, open-label, randomized, two-agent, two-cycle, two-sequence, double-crossover bioequivalence study to evaluate a single subcutaneous injection of recombinant human erythropoietin injection (CHO cells) in healthy adult male subjects
评估单次皮下注射重组人促红素注射液(CHO细胞)(1ml:4000IU,注射液)与注射用重组人促红素(CHO细胞)(4000IU/瓶,粉针)后,健康成年男性受试者的药代动力学特征,判断两种制剂是否具有生物等效性。
[Translation] To evaluate the effects of a single subcutaneous injection of recombinant human erythropoietin injection (CHO cells) (1ml: 4000IU, injection) and recombinant human erythropoietin for injection (CHO cells) (4000IU/bottle, powder injection) in healthy adult males. The pharmacokinetic characteristics of the subjects were used to determine whether the two preparations were bioequivalent.